CompletedNCT00892125
Official study titleEvaluation of the Effect of Carbamazepine on the Steady-state Pharmacokinetics of Paliperidone Extended Release in Clinically Stable Subjects With Schizophrenia or Bipolar I Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarity, SchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00838669
Official study titleEvaluation of the Effect of Food and Posture on the Pharmacokinetics of Paliperidone After a Single Administration of 12 mg ER OROS Paliperidone to Healthy Men
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00892320
Official study titleA Randomized, Open-label, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Subjects
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 20–45
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT01116830
Official study titleA Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder
This study has finished and is no longer accepting participants.
In OrangeburgSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Hoffmann-La Roche
CompletedNCT00077727
About this title
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
Read the official source — NCT00077727Official study titleA Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT06259526
Official study titleA Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
This study has finished and is no longer accepting participants.
Multiple locations, including BeijingDepressionMedication studyAges 18–65
- Countries
- China
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
CompletedNCT00253136
About this title
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
Read the official source — NCT00253136Official study titleRisperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Janssen, LP
CompletedNCT00246220
About this title
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
Read the official source — NCT00246220What is this study about?This study evaluated the safety and effectiveness of methylphenidate hydrochloride for people with ADHD.
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 18–65
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
CompletedNCT00253149
About this title
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
Read the official source — NCT00253149What is this study about?This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 18–65
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00249132
About this title
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
Read the official source — NCT00249132Official study titleRisperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen, LP
CompletedNCT00249119
About this title
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
Read the official source — NCT00249119Official study titleRisperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen, LP
CompletedNCT00253162
About this title
A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol
Read the official source — NCT00253162What is this study about?This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 18+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.